184 results about "Angiogenesis growth factor" patented technology

The invention discloses a filling and repairing agent for promoting angiogenesis and a preparation method thereof, the filling and repairing agent is composed of a vascular endothelial cell supernatant, acellular matrix particles, a suspending aid and a protective agent, the vascular endothelial cell supernatant is prepared by inducing vascular endothelial cells into a tube under a low-oxygen three-dimensional condition, collecting a cell culture solution, centrifuging and concentrating; the acellular matrix particles are obtained by acellular tissue matrix, shearing, freeze-drying, liquid nitrogen grinding and collecting; according to the filling repairing agent for promoting angiogenesis, the vascular endothelial cell supernate and the acellular matrix particles are combined, the filling repairing agent contains high-concentration angiogenesis-related factors and a stable three-dimensional bionic scaffold structure, function complementation is achieved through the synergistic effect of the bioactive factors and the bionic scaffold, and the filling repairing agent for promoting angiogenesis is obtained. Therefore, the filling repair agent which can promote angiogenesis, construct a physical support framework and promote tissue repair and regeneration capacity is innovatively obtained.

The invention discloses a bletilla striata polysaccharide hydrogel dressing and a preparation method and application thereof.The preparation method of the bletilla striata polysaccharide hydrogel dressing comprises the following steps that a carboxymethyl chitosan solution, a bletilla striata polysaccharide solution and cinnamyl aldehyde are mixed and stirred to be uniform at the temperature of 20-30 DEG C, a mixed solution system is prepared, and then standing is conducted to form gel; wherein the volume ratio of the carboxymethyl chitosan solution to the bletilla striata polysaccharide solution is (1-5): 1, and the concentration of the cinnamyl aldehyde in the mixed solution system is 0.05-5 wt%. The preparation process is simple, the raw materials are all green and natural sources, and the prepared hydrogel is good in biocompatibility, has good antibacterial, anti-inflammatory and angiogenesis promoting effects and can accelerate diabetic wound repair.

The invention belongs to the technical field of biological materials, and particularly relates to nano composite hydrogel as well as a preparation method and application thereof. In the preparation process of the hydrogel, preparation of gelatin hydrazide and preparation of pullulan oxidation are sequentially completed, then preparation of active component loaded PLGA nanoparticles and self-assembly coating with metal-polyphenol are completed, and finally, the metal-polyphenol coated PLGA nanoparticles are mixed with gelatin hydrazide and pullulan oxidation to form gel in situ. The hydrogel has the characteristics of injectability, self-healing, wet adhesion and the like, the metal-polyphenol layer has the effects of resisting inflammation, resisting oxidation and promoting angiogenesis and generates photo-thermal response to near infrared rays, on-demand controllable release of the drug-loaded nanoparticles is achieved, the composite hydrogel can improve the wound surface microenvironment, promote angiogenesis and inhibit inflammation and scar formation, and the drug-loaded nanoparticles can be applied to wound healing. The ointment is suitable for burns, scalds and various complex wounds.

A preparation method for a micro-vehicle formed by enveloping siRNA-loaded polypeptide dendrimer nanogel with a cell membrane of engineered MSCs, and the use of same. The method comprises: using lentivirus-mediated gene transfection technology for constructing MSCs that highly express CXCR4 and PSGL-1; using cytokinin B for stimulating a cell to generate vesicles, and then performing centrifugation to collect the vesicles; by means of the electrostatic attraction between polypeptide dendrimer nanoparticles and siRNAs, attaching the siRNAs of IL-6 and HIF-1α into the polypeptide dendrimer nanoparticles; and by means of using a membrane extruder, enveloping the siRNA-loaded polypeptide dendrimer nanogel with the cell membrane. The prepared micro-vehicle exhibits a good property of aggregating at inflammatory blood vessel sites and a targeting function for joint cavities with rheumatoid arthritis. In addition, the loaded siRNAs can inhibit the expressions of IL-6 and HIF-1α in the joint cavities and inhibit the cell migration and angiogenesis. The micro-vehicle targeting inflammation sites has the advantages of excellent biocompatibility, ideal siRNA loading ratio, good inflammation targeting function, etc.

The invention discloses an application of alpha-ketoglutaric acid in preparation of a medicine for promoting hypertension angiogenesis, belongs to the technical field of biological medicines, and finds that the alpha-ketoglutaric acid has the effects of promoting hypertension angiogenesis and improving microcirculation injury for the first time, and provides a new thought for diagnosis and treatment of sparse microcirculation. Alpha-ketoglutaric acid has good drug safety and a strong angiogenesis promoting effect, and can be used as a candidate drug for promoting angiogenesis. And the DM-alpha KG is alpha-ketoglutaric acid which can be absorbed by cells, can be dissolved in DMSO, and is good in stability, low in cytotoxicity and good in drug safety. Results show that the alpha-ketoglutaric acid has relatively good drug safety and relatively strong angiogenesis promoting effect, and can be used as a candidate drug for improving sparse blood vessels.

Provided are an AAV virus vector expressing an anti-VEGF fusion protein or antibody and a use of the AAV virus vector. Specifically, provided are a recombinant AAV virus vector comprising a nucleotide sequence encoding an anti-VEGF fusion protein or antibody, and a use of the recombinant AAV virus vector. The recombinant AAV virus exhibits an excellent infection effect in human cells and mouse cells, is stably and abundantly expressed within cells, and can effectively inhibit intraocular VEGF, and reduce leakage and angiogenesis caused by laser damage. Moreover, the AAV virus can be utilized to deliver an anti-VEGF fusion protein or an anti-VEGF antibody in the administration manner of subretinal injection, so that the objective of a single injection with long-term effectiveness is achieved; thus, the AAV virus can be used to prepare a drug for treating VEGF related diseases, and has broad market prospects.

The invention discloses a composition based on an engineered stem cell exosome and application of the composition in treating male sexual dysfunction. The composition comprises a mesenchymal stem cell exosome modified by genetic engineering, and the surface of the mesenchymal stem cell exosome displays a bifunctional fusion polypeptide targeting TbetaR II and LOXL2. According to the fusion polypeptide, TbetaR-PEP and LOXL2-PEP are integrated through a flexible linker, and an HIV-TAT penetrating peptide and a self-assembly motif are introduced, so that nanoparticles are formed, and the half-life period is prolonged. In-vitro experiments show that the inhibition efficiency of the fusion polypeptide on TbetaRII and LOXL2 is obviously superior to that of a single peptide, and the fusion polypeptide can synergistically reverse fibrosis and promote angiogenesis. Animal experiments prove that the exosome loaded with the fusion polypeptide can significantly improve the erectile function of diabetic ED rats. According to the invention, a radical treatment scheme is provided for male sexual dysfunction through double-target cooperation, long-acting delivery and a multi-effect repair mechanism.

The application provides a thermoelectric hydrogel composite dressing for promoting repair of diabetic ulcers and loading of targeted modified exosomes and a preparation method, which comprises the following steps: preparing methacrylated hyaluronic acid; preparing polyether F127 diacrylate; co-incubating exosomes with palmitic acid grafted targeting peptides to prepare targeted modified exosomes; mixing the methacrylated hyaluronic acid, the polyether F127 diacrylate, a photosensitizer, the targeted modified exosomes and an electrolyte, and crosslinking under ultraviolet light to form a composite gel. The composite dressing is a novel composite dressing for thermoelectric stimulation and exosome treatment. On one hand, the dressing generates a wireless and passive electric field to simulate the endogenous electric field in the wound, promote directional migration of skin cells, accelerate reepithelialization and dermal formation; on the other hand, the dressing releases exosomes to precisely target blood vessels of a wound lesion, reverse endothelial dysfunction in a high-sugar environment and promote angiogenesis, and effectively solves the problems in repair and regeneration of diabetic ulcer wounds.

The invention provides an application of a super enhancer inhibitor JQ-1 in preparation of peripheral artery disease related drugs, relates to the technical field of biomedicine, and discloses a core effect of the super enhancer inhibitor JQ-1 in peripheral artery disease ischemia repair. The traditional Chinese medicine composition can significantly accelerate blood flow recovery of ischemic limbs, up-regulate mRNA and protein expression of a vascular marker CD31 in gastrocnemius muscle tissues, effectively increase vascular density and promote angiogenesis. Aiming at the defects of the existing treatment means in the aspect of ischemic tissue angiogenesis, the application provides a brand new molecular targeted treatment scheme for high-risk groups such as patients with diabetes-related peripheral artery diseases, and can significantly reduce the risk of lower limb amputation and the incidence rate of related cardiovascular adverse events such as coronary heart disease and stroke; the technical blank of specific targeted therapy of peripheral artery diseases is filled, a solid scientific basis and a key direction are provided for research and development of novel drugs, and the specific targeted therapy method has extremely high clinical application value and wide research and development prospects.

The invention relates to the technical field of medical instruments, in particular to a photo-piezoelectric hydrogel dressing for wound repair. The hydrogel dressing realizes self-energized micro-electrical stimulation and anti-oxidation-antibacterial-anti-inflammatory integrated treatment through'energy-drug 'double closed-loop synergy: the PVDF / ZnO nanofiber on the upper layer can convert human body micro-motion and external light into micro-electrical stimulation to promote cell migration, proliferation and angiogenesis; the curcumin at the lower layer cooperates with the nano-silver to block the'oxidative stress-inflammation-infection 'vicious circle of chronic wounds. The dressing is soft and fit, does not need an external power supply, is excellent in biocompatibility, provides a self-driven multifunctional nursing scheme for refractory wounds, and has wide clinical popularization and market application prospects.

According to the application of the dipsacus asper saponin VI in regulating and controlling the differentiation of the surface stem cells, the brand new pharmacological action of the dipsacus asper saponin VI in targeted promotion of the differentiation of the epidermal stem cells is found for the first time, the cognitive limitation of the prior art is broken through, a brand new target spot and direction are provided for research and development of innovative drugs for wound repair, and the application of the dipsacus asper saponin VI in regulating and controlling the differentiation of the epidermal stem cells is realized. A medicine containing teasel saponin VI is adopted, epidermal stem cells are taken as a core target, wound reepithelialization is accelerated by promoting directional differentiation of the epidermal stem cells, the mechanism is clear, the targeting property is high, a core link capable of directly hitting wound healing is adopted, epidermal stem cell differentiation is regulated in a targeted manner, and meanwhile, the medicine has the synergistic effects of resisting inflammation and promoting angiogenesis; the obvious application potential is realized on refractory wounds such as diabetic feet and pressure sores.

The invention relates to antioxidant sonodynamic hydrogel as well as a preparation method and application thereof, the yield and sonodynamic performance of ROS (reactive oxygen species) can be improved, and the prepared hydrogel can realize efficient antibiosis in the early stage of infection, exert antioxidant and repair promoting effects in the later stage of infection, and can promote angiogenesis and collagen deposition, optimize inflammation and immune microenvironment, improve the immunity of the ROS and improve the ROS yield and the sonodynamic performance of the ROS. The dynamic balance of antibiosis, antioxidation and healing promotion is realized, and the treatment effect is comprehensively improved.

The invention discloses a preparation method and application of dual-network piezoelectric induction hydrogel with a piezoelectric effect, and the method comprises the following steps: taking ACG and GelMA as base materials, taking MBA as a cross-linking agent, cooperating with a photoinitiator, and carrying out free radical polymerization to form a precursor solution; and adding BTO nanoparticles, mixing, and curing to obtain the hydrogel. According to the hydrogel disclosed by the invention, the mechanical property and the structural stability of the material are remarkably enhanced through a double-network structure, and the defects that traditional hydrogel is prone to excessive deformation and insufficient in mechanical property are overcome; by introducing a functional component with piezoelectric property, the material can generate a stable electric signal under the action of external force, the local electrophysiological environment of a wound surface is improved, cell proliferation, migration and angiogenesis are promoted, and tissue repair is accelerated; the anti-infection function can be further achieved while electrical regulation and control are achieved, the limitation of a single drug loading or passive protection strategy is avoided, drug resistance and toxic and side effect risks are reduced, and the synergistic effect of antibiosis and regeneration is achieved.

The present invention discloses a hydrogel and its application in ischemic heart disease, relating to the technical field of myocardial infarction repair. The present invention provides a multifunctional hydrogel with injectability, enabling in-situ injection. This hydrogel combines the comprehensive characteristics of improving the conductivity of the infarcted area, generating oxygen, scavenging ROS, promoting M2 polarization of macrophages, and promoting angiogenesis. Its excellent performance is outstanding in alleviating MI / RI, improving the local microenvironment, and enhancing myocardial repair function, providing a new direction for the treatment of heart injury. At the same time, the CSA-δ hydrogel formed after loading drugs has the ability of drug sustained release, which enables the drugs to be released continuously and stably, thereby prolonging the drug action time.

The invention discloses a GLP-1 (32-36) engineered exosome and application of the GLP-1 (32-36) engineered exosome in drugs and instruments for preventing and / or treating diabetic lower limb arterial lesion. The preparation process and related characteristics of the GLP-1 (32-36) engineered exosome are respectively as shown in figures (1) and (2). The exosome is prepared by treating human pluripotent stem cells by using GLP-1 (32-36). The GLP-1 (32-36) engineered exosome has relatively high activity in plasma, and the enterotrypsin synthetic peptide can effectively improve the yield of the exosome and further optimize the function of the exosome, so that a stronger therapeutic effect of promoting angiogenesis after ischemia is exerted. The GLP-1 (32-36) engineered exosome disclosed by the invention also has safety and can be used for a treatment strategy of diabetic lower limb artery complications.

The present application relates to the technical field of wound repair, and provides a traditional Chinese medicine composition for promoting wound healing and a preparation method thereof.The traditional Chinese medicine composition comprises a first traditional Chinese medicine composition and a second traditional Chinese medicine composition which are applied to the acute phase and the repair proliferation phase.The former comprises naked flower purple perilla extract, nectarine leaf extract, purple perilla extract, dragon's blood micro powder, spironast extract, centella asiatica volatile oil, rhubarb extract, borneol, mussel mucin, medicinal glycerol and purified water.The latter comprises red algae extract, nectarine leaf extract, radix astragali extract, panax notoginseng total saponins, aloe extract, dendrobium officinale extract, sea buckthorn extract, pinctada martensii purified peptide, snail glycosaminoglycan, medicinal glycerol and purified water.The composition can play the roles of antibiosis, anti-inflammation, hemostasis, analgesia and astringency in the acute phase, and can promote angiogenesis, collagen synthesis and epithelial regeneration in the repair proliferation phase, so that the wound is rapidly repaired and healed.

The invention relates to the field of biological medicines, in particular to an angiogenesis inhibition polypeptide specifically bound with an ITB3 target or pharmaceutically acceptable salt thereof, which is characterized in that the polypeptide is a) or b) or c) as follows: a) a polypeptide shown in any one amino acid sequence in SEQ ID NO: 1-7, b) a polypeptide shown in any one amino acid sequence in SEQ ID NO: 2-7, and c) a polypeptide shown in any one amino acid sequence in SEQ ID NO: 3-7; b) a derivative polypeptide obtained by adding more than one amino acid residue to the amino terminal and / or carboxyl terminal of the polypeptide shown in any one amino acid sequence in SEQ ID NO: 1-7; and c) a derivative polypeptide obtained by adding or replacing more than one amino acid at any site of the polypeptide shown as any one amino acid sequence in SEQ ID NO: 1-7 except the amino terminal and the carboxyl terminal. The angiogenesis inhibiting polypeptide provided by the invention can specifically recognize and bind ITB3, can effectively inhibit angiogenesis, endothelial cell invasion and migration and target transfer in in-vivo and in-vitro experiments, is efficient and low in toxicity, and has potential effects of treating individual tumors, diabetic vascular proliferative diseases, rheumatoid arthritis and neovascular eye diseases.

The present invention discloses a class of pyrimidopyrimidone compounds and applications thereof. The compounds have excellent inhibitory activity on cyclin-dependent kinases 2 / 4 / 6 (CDK2 / 4 / 6), can be used as CDK2 / 4 / 6 inhibitors, and are used to prepare drugs for preventing and / or treating diseases related to CDK2 / 4 / 6 overexpression in organisms and drugs for diseases related to angiogenesis or cancer metastasis.

The invention discloses a polysaccharide-tea polyphenol-metal compound, which is formed by dispersing a metal-tea polyphenol nano ligand in polysaccharide gel formed by covalent crosslinking of atractylodes macrocephala polysaccharide and sodium alginate, and the metal-polyphenol nano ligand is a nano complex formed by coordination of tea polyphenol and metal ions. The invention also discloses a preparation method and application thereof. The rhizoma atractylodis macrocephalae polysaccharide-sodium alginate-tea polyphenol derivative-metal composite system disclosed by the invention not only can improve the stability and release behavior of tea polyphenol in vivo, but also can regulate and control an immunometabolism microenvironment in a bone repair process, induce inflammation resolution and promote angiogenesis and bone matrix deposition, so that the bone repair effect is improved. Multiple synergistic effects of inflammation resistance, oxidation resistance, vascularization promotion and osteogenesis induction are realized, so that repair and regeneration of skull defects are remarkably accelerated, and a new intelligent immunometabolism regulation strategy is provided for repair of complex bone defects.

The invention discloses a preparation method of a pyridopyrimidine compound and application of the pyridopyrimidine compound in preparation of an asthma medicine. The pyridopyrimidine compound provided by the invention is applied to preparation of medicines for preventing / treating asthma, DPPO is applied to prevention and treatment of bronchial asthma, and a new medicine choice is brought to asthma patients. Experimental results show that the DPPO can obviously inhibit attack of asthma and secretion of related inflammatory factors such as IL-1beta, IL-4, IL-5, IL-6, IL-13 and IL-17A, has a relaxation effect on tracheal smooth muscles, has the effects of resisting angiogenesis, airway remodeling and inflammation, and achieves the effect of treating asthma. In addition, current researches show that the asthma pathogenesis is very complex, DPPO can obviously improve pathological changes of mouse lung tissues sensitized by house dust mite extract (HDM) and toluene diisocynate (TDI), and the DPPO has certain universality and can be speculated to have huge application potential in research and development of drugs for treating various asthma.

The application relates to the application of lycorine hydrochloride in the preparation of a medicine for inhibiting the proliferation of a neointimal in a blood vessel. Lycorine hydrochloride has the effect of inhibiting the proliferation of a neointimal in a blood vessel, and the effect is mainly realized by inhibiting the proliferation and migration of vascular smooth muscle cells. In the body, the results show that lycorine hydrochloride can significantly inhibit the intimal proliferation caused by left common carotid artery ligation, and in vitro experiments prove that lycorine hydrochloride can intervene in the proliferation, migration and phenotype transformation of VSMCs induced by PDGF-BB. Lycorine hydrochloride inhibits the proliferation, migration and phenotype transformation of VSMCs induced by PDGF-BB, and the proliferation of a neointimal in a blood vessel through a MAPKs signal path. The application provides data for preparing lycorine hydrochloride into a medicine for inhibiting the proliferation of a neointimal in a blood vessel, and is expected to be applied to the prevention and treatment of complications after percutaneous coronary intervention, such as restenosis or in-stent thrombosis, and can become a potential medicine for intervening in restenosis.

This application relates to the fields of biomedicine and wound repair technology, and particularly to the application of platelet exosomes in the treatment of diabetic wound healing. This application discloses the use of platelet exosomes in the preparation of products having one or more of the following functions: 1) prevention and / or treatment of diabetic foot; 2) promotion of wound healing and / or tissue repair; 3) shortening wound healing time; 4) promoting granulation tissue growth; 5) enhancing wound angiogenesis; 6) alleviating inflammatory responses; 7) inhibiting the expression of pro-inflammatory factors; 8) promoting the expression of anti-inflammatory factors; 9) reducing MMP-9 expression; and 10) increasing MMP-2 expression. It is particularly suitable for the treatment of diabetic foot ulcers, delayed wound healing, and related complications, and also covers the use of this product in the preparation of diabetic foot treatment drugs and medical dressings.

The invention relates to an anti-VEGFA antibody or an antigen binding fragment thereof and application thereof, the anti-VEGFA antibody or the antigen binding fragment thereof has the advantages of high thermal stability, high water solubility, small molecular weight, simple expression and purification process and high affinity with VEGFA, and has the effects of effectively blocking a VEGFA signal channel, effectively blocking pathological processes such as vascular endothelial cell proliferation and angiogenesis caused by VEGFA, and improving the anti-VEGFA antibody or the antigen binding fragment thereof. The compound can be potentially applied to treatment of diseases related to VEGFA (vascular endothelial growth factor A).

This invention discloses an intestinal fungus Saccharomyces cerevisiae M7015 and its applications belong to the field of microbial technology. Saccharomyces cerevisiae The accession number for M7015 is GDMCC No. 66195. This invention first demonstrated, using a mouse subcutaneous stroma embolism model, that the aforementioned strain can promote angiogenesis; secondly, using mouse and Bama miniature pig myocardial infarction models, it was found that the aforementioned strain can promote collateral angiogenesis in ischemic areas of the heart and improve cardiac function. This invention not only fully elucidates... Saccharomyces cerevisiae M7015 promotes the formation of collateral vessels in the heart and improves cardiac function, and also reveals the broad application prospects of this bacterium in the treatment of vascular diseases.

The present application relates to the application of CircRAB3IP in the preparation of a drug for promoting angiogenesis, and belongs to the technical field of biological medicine; the present application provides the application of CircRAB3IP in the preparation of a drug for preventing or treating heart failure; in the preparation of a drug for promoting angiogenesis; in the preparation of a heart failure prognosis diagnosis kit; and in the preparation of a myocardial hypertrophy prognosis diagnosis kit; the present application proves through in-vivo and in-vitro experiments that circRAB3IP can promote angiogenesis, and can effectively improve heart function disorder caused by high blood pressure mechanical stress, slow down cardiac remodeling, myocardial fibrosis, and reduce cardiac inflammation. The present application provides a new target and theoretical basis for the treatment of hypertensive cardiac remodeling.

The application is a preparation of a composite stem cell active biomaterial and its application in artificial skin, effectively solves the problems of high production cost, complex production process and non-use for active substance research of the existing method, and comprises a double-layer composite material, the lower layer is an active material layer in the form of hydrogel composed of active liposomes and stem cells, and the upper layer is an antibacterial layer; the preparation method of the thiolated hyaluronic acid / H active factor composite hydrogel is relatively mild, does not need to add a crosslinking agent and contains a large amount of active ingredients; by using the mechanism, the environment can induce angiogenesis through endothelial cells / fat stem cells combined with active factors and platelet lysate and rapidly construct microtissues in vitro, which is beneficial to the scaffold in large-scale cultivation of artificial skin basement layer in vitro to meet the needs of patients.

The invention relates to a preparation method and application of macroporous alanine modified nanocellulose-based dynamic hydrogel, and the preparation method comprises the following steps: S1, by taking alanine and nanocellulose as raw materials, synthesizing alanine modified nanocellulose through esterification reaction; s2, phenylboronic acid and beta-cyclodextrin are used as raw materials, and phenylboronic acid modified cyclodextrin is synthesized through a substitution reaction; and S3, introducing the Ala-CNFs into a polyvinyl alcohol and PBCD system, so as to obtain the macroporous alanine modified nano cellulose based dynamic hydrogel. The synthesis and preparation method of the hydrogel has the characteristics of being green and environment-friendly, alanine can be grafted on nano cellulose in an aqueous solution environment, and the problem that tissue regeneration is hindered due to the fact that an existing injectable hydrogel adhesive occupies the space of angiogenesis and tissue regeneration in the wound healing process can be effectively solved. The hydrogel has the characteristics of injectability, self-healing, shape adaptability, biological tissue adhesion, biodegradability, biocompatibility, hemostasis, and promotion of tissue regeneration and angiogenesis.

The invention relates to structures and preparation methods of nine novel guaiane type sesquiterpene dimer compounds in xylostemma oblongifolium, and applications of the dimer compounds in anti-angiogenesis and anti-tumor aspects. The structures of the compounds are as shown in Figure 1. The invention also relates to a preparation method of the dimer compounds, and an application of the dimer compounds in anti-angiogenesis and anti-tumor aspects. The compound provided by the invention has angiogenesis inhibition activity and can be used for development and application of antitumor drugs.

The invention provides a functional nerve conduit modified by a smooth muscle extracellular matrix as well as a preparation method and application of the functional nerve conduit, and belongs to the field of biological tissue materials. Smooth muscle cells are inoculated to the surface of a material, the functional nerve conduit is prepared through smooth muscle cell-derived extracellular matrix modification, the nerve conduit remarkably promotes dorsal root ganglion and PC12 axon regeneration, angiogenesis is promoted by inducing Schwann cell migration and VEGF secretion, a guiding bridge is provided for new axon, and the nerve conduit has the advantages that the nerve conduit has a good application prospect. The cut-off nerve is reconnected, the large-segment defective sciatic nerve is repaired, the function control and the muscle function after nerve regeneration are improved, and good application prospects are achieved.

The application discloses a composite hydrogel based on urethral stem cell membrane sheet ECM and exosomes and a preparation method and application thereof, and relates to the technical field of tissue engineering, and in particular relates to a soluble ECM protein solution obtained by dissolving and enzymatically hydrolyzing urethral stem cell membrane sheet decellularized matrix (ECM) powder and mixing the soluble ECM protein solution with exosomes in a mass ratio of 3:1-10:1, and performing temperature-sensitive crosslinking in DMEM at pH 7.0 and 36-38 DEG C to form a hydrogel. The composite hydrogel based on urethral stem cell membrane sheet decellularized matrix (ECM) and exosomes integrates the cell activity of the urethral stem cell membrane sheet, the structural support of the decellularized matrix (ECM) and the signal regulation of the exosomes, constructs a three-level functional system, forms a synergistic repair effect, and is helpful to promoting angiogenesis in the urethra. Through covalent coupling of the decellularized matrix (ECM) fiber network and the surface protein of the exosomes, the intelligent release of the exosomes in an inflammatory environment is realized, and the composite hydrogel is used for urethral repair and angiogenesis promotion.